CytomX Therapeutics (CTMX) Share-based Compensation (2014 - 2026)

CytomX Therapeutics' Share-based Compensation history runs 13 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• Quarterly Share-based Compensation rose 134.36% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (up 7.3% YoY) and the FY2025 annual result came in at $7.3 million, down 4.8% from the prior year.
• Share-based Compensation was $4.7 million for Q1 2026 at CytomX Therapeutics, up from $1.5 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $4.7 million in Q1 2026 and bottomed at -$10.5 million in Q4 2022.
• A 5-year average of $1.2 million and a median of $1.9 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation plunged 396.28% — and 2026, when it jumped 134.36%.
• CytomX Therapeutics' Share-based Compensation stood at -$10.5 million in 2022, then soared by 124.3% to $2.6 million in 2023, then decreased by 26.18% to $1.9 million in 2024, then decreased by 21.5% to $1.5 million in 2025, then surged by 218.19% to $4.7 million in 2026.
• Business Quant data shows CTMX's Share-based Compensation at $4.7 million in Q1 2026, $1.5 million in Q4 2025, and $800000.0 in Q3 2025.